In COVID 19, Do we need surfactant therapy
Ghaleb, A., Mahmoud, H. (2020). In COVID 19, Do we need surfactant therapy. EKB Journal Management System, 3(COVID-19), 10-12. doi: 10.21608/niles.2020.31898.1024
Alaa Ghaleb; Hossamelden Mahmoud. "In COVID 19, Do we need surfactant therapy". EKB Journal Management System, 3, COVID-19, 2020, 10-12. doi: 10.21608/niles.2020.31898.1024
Ghaleb, A., Mahmoud, H. (2020). 'In COVID 19, Do we need surfactant therapy', EKB Journal Management System, 3(COVID-19), pp. 10-12. doi: 10.21608/niles.2020.31898.1024
Ghaleb, A., Mahmoud, H. In COVID 19, Do we need surfactant therapy. EKB Journal Management System, 2020; 3(COVID-19): 10-12. doi: 10.21608/niles.2020.31898.1024

In COVID 19, Do we need surfactant therapy

NILES journal for Geriatric and Gerontology
Contributors, Volume 3, COVID-19, July 2020, Page 10-12  XML PDF (458.58 K)
DOI: 10.21608/niles.2020.31898.1024
View on SCiNiTO View on SCiNiTO
Authors
Alaa Ghaleb email 1; Hossamelden Mahmoud2
1Internal Medicine department, Sohag university, Sohag, Egypt
2Internal Medicine Department, Qena University, Qena , Egypt
Abstract
In premature neonates with a primary surfactant deficiency , there is ARDS and surfactants is the main line of therapy. Now it is well known that the virus is attached to and is replicated within type 11 pneumocytes, the main function of these cells is production of surfactants which decrease surface tension and keep the alveoli patent without collapse. In this condition there is a secondary surfactant deficiency which may play a role in pathogenesis and deterioration of patient clinical condition.
So, I suggest that treatment by surfactant therapy either derived from endogenous or exogenous source in severe cases can improve clinical condition, delay or avoid patient ventilation by refilling debilitated surfactants and lavage of bronchial tree, this directly decrease mortality rate.

In premature neonates with a primary surfactant deficiency , there is ARDS and surfactants is the main line of therapy. Now it is well known that the virus is attached to and is replicated within type 11 pneumocytes, the main function of these cells is production of surfactants which decrease surface tension and keep the alveoli patent without collapse. In this condition there is a secondary surfactant deficiency which may play a role in pathogenesis and deterioration of patient clinical condition
Keywords
COVID 19; surfactant therapy; ARDS
References

1.Saif ATS, Saif PS , El Deeb A. Role of amniotic membrane transplantation in symblepharon. Guoji Yanke Zazhi(Int Eye Sci) 2017;17(5):819-824

2.Nassar M, Saif M, Saif A, Saif P. Sensitivity and specificity of nassar color test in early detection of diabetic macular edema. Journal of Retina-Vitreous. 2016;24:109-113.

3.Amer, S. , Saif, M. , Saif, A. and Saif, P. (2014) Variations of Cup-to-Disc Ratio in Children. Open Journal of Ophthalmology, 4, 12-17. doi: 10.4236/ojoph.2014.41003.

Statistics
Article View: 282
PDF Download: 481